<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140956</url>
  </required_header>
  <id_info>
    <org_study_id>3112006</org_study_id>
    <nct_id>NCT03140956</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Levodopa Study in Healthy Males</brief_title>
  <official_title>Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate PK of levodopa in plasma after repeated doses of 3&#xD;
      levodopa formulations given in combination with carbidopa and ODM-104 and compared to the PK&#xD;
      of standard IR and CR levodopa formulations in the same combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">August 3, 2017</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax) of levodopa</measure>
    <time_frame>24 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Levodopa formulation D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa formulation E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa formulation F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa formulation F</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet IR 100/25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet IR 100/25MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet CR 100/25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinemet IR 100/25MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-104 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ODM-104 100MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbidopa 20MG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 65mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbidopa 65MG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa, carbidopa, ODM-104</intervention_name>
    <description>Crossover design. Study treatments will be administered in randomized order 4 times a day.</description>
    <arm_group_label>Carbidopa 20mg</arm_group_label>
    <arm_group_label>Carbidopa 65mg</arm_group_label>
    <arm_group_label>Levodopa formulation D</arm_group_label>
    <arm_group_label>Levodopa formulation E</arm_group_label>
    <arm_group_label>Levodopa formulation F</arm_group_label>
    <arm_group_label>ODM-104 100mg</arm_group_label>
    <arm_group_label>Sinemet CR 100/25mg</arm_group_label>
    <arm_group_label>Sinemet IR 100/25mg</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  Finnish speaking males between 18-65 years of age.&#xD;
&#xD;
          -  Body mass index (BMI) between 19-32 kg/m2 (BMI = weight/height2).&#xD;
&#xD;
          -  Weight at least 60 kg.&#xD;
&#xD;
          -  Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or&#xD;
             other intestinal problems, and no history of major gastrointestinal surgery).&#xD;
&#xD;
          -  Sexually active study subjects, unless surgically sterile must adhere to a proper form&#xD;
             of contraception (hormonal contraception or intrauterine device on female partner and&#xD;
             an additional barrier method used at least by one of the partners) and must not donate&#xD;
             sperm from the first study treatment administration until 3 months after the last&#xD;
             study treatment administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease&#xD;
             or cancer (except local non-melanoma skin cancer) within the previous 2 years.&#xD;
&#xD;
          -  Any condition requiring regular concomitant treatment (including vitamins and herbal&#xD;
             products) or likely to need any concomitant treatment during the study. As an&#xD;
             exception, paracetamol for occasional pain is allowed.&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory value or ECG (such as prolonged QTcF &gt;&#xD;
             450 ms or QRS &gt; 120 ms) that in the opinion of the investigator could interfere with&#xD;
             the interpretation of study results or cause a health risk for the subject if he takes&#xD;
             part in the study.&#xD;
&#xD;
          -  Known hypersensitivity to the active substances or the excipients of the drugs.&#xD;
&#xD;
          -  History of vasovagal collapses or vagal reactions with unexplained reason within the&#xD;
             previous 2 years or a tendency for vasovagal reactions during blood sampling.&#xD;
&#xD;
          -  HR &lt; 40 beats per minute (bpm) or &gt; 90 bpm in the supine position after 5 min rest at&#xD;
             the screening visit.&#xD;
&#xD;
          -  At the screening visit:systolic BP &lt; 90 mmHg or &gt; 150 mmHg in the supine position&#xD;
             after 5 min rest and diastolic BP &lt; 50 mmHg or &gt; 90 mmHg in the supine position after&#xD;
             5 min rest.&#xD;
&#xD;
          -  History of anaphylactic/anaphylactoid reactions.&#xD;
&#xD;
          -  Strong tendency to motion sickness.&#xD;
&#xD;
          -  Recent or current (suspected) drug abuse.&#xD;
&#xD;
          -  Recent or current alcohol abuse; regular drinking of more than 21 units per week (1&#xD;
             unit = 4 cl spirits or equivalent).&#xD;
&#xD;
          -  Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day&#xD;
             and/or inability to refrain from the use of nicotine containing products during the&#xD;
             study (from the screening visit to the end-of-study visit).&#xD;
&#xD;
          -  Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability&#xD;
             to refrain from using caffeine containing beverages 10 h before and during the study&#xD;
             periods.&#xD;
&#xD;
          -  Blood donation or loss of a significant amount of blood within 90 days before the&#xD;
             first study treatment administration.&#xD;
&#xD;
          -  Participation in an investigational drug study or administration of an investigational&#xD;
             drug within 90 days before the first study treatment administration.&#xD;
&#xD;
          -  Unsuitable veins for repeated venipuncture or cannulation.&#xD;
&#xD;
          -  Predictable poor compliance or inability to communicate well with the study centre&#xD;
             personnel.&#xD;
&#xD;
          -  Inability to participate in all treatment periods.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit, Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <zip>02200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

